Skip to main content

Raghuram Selvaraju

Stock Analyst at H.C. Wainwright

Total Price Targets
26
Stocks Covered
19
Sectors
Healthcare, Technology
Most Recent
Mar 4, 2026

Notable Calls (Last 12 Months)

Most Bullish

  • MLTX+197.0%
    MoonLake Immunotherapeutics
    $30.00 targetNov 3, 2025
  • SLNO+159.8%
    Soleno Therapeutics, Inc.
    $100.00 targetMar 4, 2026
  • CLYM+158.8%
    Climb Bio, Inc.
    $11.00 targetDec 18, 2025

Most Bearish

  • RYTM+9.7%
    Rhythm Pharmaceuticals, Inc.
    $123.00 targetDec 22, 2025
  • RYTM+10.9%
    Rhythm Pharmaceuticals, Inc.
    $110.00 targetSep 29, 2025
  • AXSM+11.9%
    Axsome Therapeutics, Inc.
    $200.00 targetJan 5, 2026

Stocks Covered by Raghuram Selvaraju

SymbolCompanyLatest TargetCurrent PriceUpside# TargetsLast Updated
SLNOSoleno Therapeutics, Inc.$100.00$52.86+89.2%2Mar 4, 2026
BBIOBridgeBio Pharma, Inc.$100.00$69.25+44.4%3Feb 17, 2026
RAREUltragenyx Pharmaceutical Inc.$50.00$24.79+101.7%1Feb 17, 2026
AXSMAxsome Therapeutics, Inc.$200.00$204.09-2.0%2Jan 5, 2026
RYTMRhythm Pharmaceuticals, Inc.$123.00$82.41+49.3%3Dec 22, 2025
CLYMClimb Bio, Inc.$11.00$8.97+22.6%1Dec 18, 2025
GANXGain Therapeutics, Inc.$8.00$1.90+321.1%1Dec 1, 2025
BNTCBenitec Biopharma Inc.$32.00$11.98+167.1%1Nov 24, 2025
MLTXMoonLake Immunotherapeutics$30.00$16.71+79.5%2Nov 3, 2025
RVMDRevolution Medicines, Inc.$62.00$140.52-55.9%1Nov 4, 2024
ADMAADMA Biologics, Inc.$18.00$10.47+71.8%1Oct 14, 2024
LGVNLongeveron Inc.$10.00$0.88+1036.6%1Jul 29, 2024
OVIDOvid Therapeutics Inc.$3.00$2.79+7.3%1Jul 2, 2024
TRDAEntrada Therapeutics, Inc.$18.00$14.45+24.6%1Jun 25, 2024
URGNUroGen Pharma Ltd.$60.00$23.37+156.7%1Jun 14, 2024
BTAIBioXcel Therapeutics, Inc.$10.00$1.22+719.7%1Apr 15, 2024
BDTXBlack Diamond Therapeutics, Inc.$12.00$2.60+362.4%1Mar 18, 2024
AQSTAquestive Therapeutics, Inc.$9.00$4.18+115.1%1Mar 18, 2024
ACMRACM Research, Inc.$17.65$52.45-66.4%1Jul 3, 2023

Recent Activity

  • Mar 4, 2026— Set$100.00price target onSLNO(Soleno Therapeutics, Inc.)
  • Feb 17, 2026— Set$50.00price target onRARE(Ultragenyx Pharmaceutical Inc.)
  • Feb 17, 2026— Set$100.00price target onBBIO(BridgeBio Pharma, Inc.)
  • Jan 5, 2026— Set$200.00price target onAXSM(Axsome Therapeutics, Inc.)
  • Dec 22, 2025— Set$123.00price target onRYTM(Rhythm Pharmaceuticals, Inc.)
  • Dec 18, 2025— Set$11.00price target onCLYM(Climb Bio, Inc.)
  • Dec 1, 2025— Set$8.00price target onGANX(Gain Therapeutics, Inc.)
  • Nov 24, 2025— Set$32.00price target onBNTC(Benitec Biopharma Inc.)
  • Nov 3, 2025— Set$30.00price target onMLTX(MoonLake Immunotherapeutics)
  • Sep 29, 2025— Set$110.00price target onRYTM(Rhythm Pharmaceuticals, Inc.)
  • Aug 29, 2025— Set$70.00price target onBBIO(BridgeBio Pharma, Inc.)
  • Dec 2, 2024— Set$70.00price target onSLNO(Soleno Therapeutics, Inc.)
  • Nov 4, 2024— Set$62.00price target onRVMD(Revolution Medicines, Inc.)
  • Oct 14, 2024— Set$18.00price target onADMA(ADMA Biologics, Inc.)
  • Sep 18, 2024— Set$64.00price target onRYTM(Rhythm Pharmaceuticals, Inc.)
  • Aug 6, 2024— Set$180.00price target onAXSM(Axsome Therapeutics, Inc.)
  • Jul 29, 2024— Set$10.00price target onLGVN(Longeveron Inc.)
  • Jul 2, 2024— Set$3.00price target onOVID(Ovid Therapeutics Inc.)
  • Jul 1, 2024— Set$100.00price target onMLTX(MoonLake Immunotherapeutics)
  • Jun 25, 2024— Set$18.00price target onTRDA(Entrada Therapeutics, Inc.)

Frequently Asked Questions

Who is Raghuram Selvaraju?

Raghuram Selvaraju is a stock analyst at H.C. Wainwright covering 19 stocks primarily in Healthcare, Technology. They have issued 26 price targets since Jul 3, 2023.

What stocks does Raghuram Selvaraju cover?

Raghuram Selvaraju currently covers 19 stocks, including BBIO, RYTM, SLNO, AXSM, MLTX.

What is Raghuram Selvaraju's latest price target?

Raghuram Selvaraju's most recent price target was $100.00 on SLNO (Soleno Therapeutics, Inc.), set on Mar 4, 2026.

What is Raghuram Selvaraju's highest price target?

Raghuram Selvaraju's highest issued price target is $200.00 on AXSM, set on Jan 5, 2026.

Coverage based on publicly published price targets. Not investment advice.